A study to check the outcomes of Triple Negative Breast Cancer patients with the presence of Estrogen receptor Beta and TP53 mutation and the outcomes of adding the drug Tamoxifen in these patients.
Phase 2
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2023/09/057359
- Lead Sponsor
- AVNEET KAILASH AGRAWA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)All triple negative breast cancer patients will be included
2)All stages of breast cancer patients will be included
Exclusion Criteria
1)Luminal Breast Cancer patients
2)Pregnant females
3)Breastfeeding females
4)Patients receiving olaparib
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method